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Time-resolved emission spectra (TRES) have been used to detect conformational changes of
intrinsic tyrosines within bovine insulin at a physiological pH. The approach offers the ability to
detect the initial stages of insulin aggregation at the molecular level. The data analysis has revealed
the existence of at least three fluorescent species undergoing dielectric relaxation and significant
spectral changes due to insulin aggregation. The results indicate the suitability of the intrinsic
TRES approach for insulin studies and for monitoring its stability during storage and aggregation
in insulin delivery devices. Published by AIP Publishing. https://doi.org/10.1063/1.5008477
Protein aggregation has attracted significant interest
due to its role in neurodegenerative diseases including
Alzheimer’s disease (AD), Parkinson’s disease (PD), and
diabetes type II.1,2 Proteins and their proteolytic products
can undergo conformational changes allowing them to self-
assemble into nanostructured amyloid fibrils. Such structures
then accumulate into microscopic deposits, senile plaques,
which are found in the post-mortem brains of AD patients.
However, correlations between the amyloid fibrils and the
extent of cognitive loss have yet to be reported. By contrast,
cytotoxicity is attributed to the soluble, prefibrillar forms of
amyloid,3 whereas reducing fibril formation does not neces-
sarily lower cytotoxicity.4 Taken together, these factors sug-
gest that insoluble amyloid fibrils are the repositories of
soluble intermediates that remain in equilibrium with insolu-
ble fibrillar forms.5 Therefore, it is believed that the fibril-
type of protein aggregation should follow three main steps:
(1) misfolding of the monomeric form into a low oligomer,
which (2) nucleates the formation of elongated proto-fibrils
that (3) aggregate forming mature fibrils.6,7 Most impor-
tantly, proteopathies—neurodegenerative disorders caused
by protein misfolding and aggregation—are caused by differ-
ent proteins,6 but all result from the same generic mechanism
of fibrillogenesis. Yet, a capability to monitor this very pro-
cess of persistent protein aggregation is lacking.
One protein that is prone to fibrillation is insulin—a hor-
mone which regulates blood glucose levels within the body.
Patients with diabetes do not produce enough insulin to sta-
bilize blood glucose levels and thus need additional injec-
tions of this hormone. Insulin is an extensively studied
protein because of complications caused by its aggregation.
For example, at frequent injection sites, long fibrous insulin
structures have been found.8–10 Also, the long term storage
of insulin has been shown to lead to aggregation, thus
impacting the efficacy and cost of diabetes treatment.11
Specifically, the transportation and storage at higher temper-
atures increase the likelihood of instability since fibril and
covalent polymer formation are temperature-dependent. The
devices used in insulin infusion therapy are particularly sus-
ceptible because wearing at body heat, shaking of the reser-
voir with bubble formation, and interaction with hydrophobic
surfaces of the infusion cannula all encourage monomer for-
mation and partial monomer unfolding, the prerequisites for
fibril formation. Moreover, serum samples taken from patients
suffering from PD displayed an autoimmune response to insu-
lin fibrils, which may suggest that insulin aggregation may
play a role in neurodegenerative disease.12
Insulin13 consists of 51 residues with two polypeptide
chains, A and B. Chain A has 21 amino acid residues and a
disulphide bridge between two cysteine amino acids, while
chain B is composed of 30 amino acids. Both chains are
covalently linked together by two cysteine bridges. There are
seven intrinsic fluorophores in an insulin particle: two tyro-
sine (Tyr) residues on chain A and two Tyr and three phenyl-
alanine (Phe) residues on chain B. Insulin is predominantly
stored as a hexamer stabilized by zinc ions and favours hex-
amer conformations at pH 7.4.
Several techniques have been employed to study fibril
formation including circular dichroism (CD),14,15 transmis-
sion electron microscopy (TEM),16 atomic force microscopy
(AFM),17 X-ray diffraction,18 and others.19–21
CD spectroscopy studies showed that insulin adopts a-
helical conformations that can convert to appreciably b-
pleated structures as a function of time. X-ray diffraction
studies showed structural similarities between insulin fibrils
and other proteins associated with amyloid formation, in
which individual b-strands run perpendicular to the main
fibril axis. The cross-b fibril structure is the hallmark of amy-
loid fibrils.
Fluorescence spectroscopy is one of the most informa-
tive techniques to study protein folding and self-assembly
and to monitor conformational changes. It offers an excellent
combination of speed, ease of use, and nanometre-level
molecular information.22 Fluorescence benefits from label-
ling the protein assembly of interest with extrinsic fluoro-
phores such as Thioflavin T (ThT), Auramine O, ANS, and
Congo red13,23–25 to probe secondary structure alterations as
a function of fluorescence responses. The use of these dyesa)Electronic mail: o.j.rolinski@strath.ac.uk
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has given a deeper understanding of protein fibrillation. The
approaches used include conventional fluorescence spectra,26
fluorescence decay,27 and fluorescence correlation spectros-
copy.28 One of the main findings observed in ThT-based
experiments was ThT fluorescence intensity showing a sig-
moidal function with negligible fluorescence intensity
observed in the early stages, a gradual increase over time,
and a plateau in the final stage. As the ThT quantum yield
increases from nearly 0 to a higher value on binding to the b-
sheets of probed fibrils, this result indicates that fibril forma-
tion by insulin undergoes three stages: an initial lag phase, a
growth phase, and a final equilibrium phase.
However, the use of extrinsic fluorophores is associated
with some limitations as they can perturb protein kinetics,
which leads to ambiguities in interpretation and lacks the
sensitivity required for studying prefibrillar structures,29 and
different probes used on the same system can yield different
signals.30 In this study, we attempt to overcome these limita-
tions with the use of intrinsic fluorophores to detect confor-
mational changes during insulin fibrillation. Our premise is
that since insulin has four tyrosine residues which are sensi-
tive to the local microenvironments, their fluorescence
response may carry information relevant to the insulin aggre-
gation and fibrillation. In previous studies of tyrosine
response to insulin fibrillation, e.g.,13 its fluorescence was
monitored at the fixed wavelength only and insulin fibril for-
mation was accelerated by elevating temperatures and/or
decrease pH of the aqueous solution, which is inconsistent
with physiological conditions.
In this paper, we report insulin’s tyrosine fluorescence
intensity decay and time-resolved emission spectra (TRES)
to extract in-depth information on insulin aggregation kinet-
ics under physiological pH conditions. Using time-resolved
techniques carries significant advantages over the time-
integrated approaches,22 the latter offering limited informa-
tion on the dynamics of molecules in the excited-states.
Bovine insulin and phosphate-buffered saline pH 7.4
(PBS) were purchased from Sigma-Aldrich and were used
without further purification. 50lM solution of bovine insulin
was prepared in PBS buffer (0.01M) and sonicated until
completely dissolved. The sample was kept and measured at
22 C. The steady state absorption and fluorescence spectra
measurements were recorded using a Lambda 25 UV-Vis spec-
trometer (Perkin-Elmer) and Fluorolog (Horiba Scientific),
respectively. For TRES measurements, the fluorescence decays
were recorded on a DeltaFlex fluorescence lifetime system
(Horiba Jobin Yvon IBH Ltd, Glasgow) using time correlated
single photon counting (TCSPC). A NanoLED producing
600 ps pulses at 279 nm31 was used to excite the intrinsic
tyrosine fluorescence at detection wavelengths k ranging from
290 to 350nm at 5 nm intervals. To avoid the influence of rota-
tional effects on fluorescence decays, a vertically oriented
polariser in the excitation channel and a polarizer at the magic
angle (54.7) in the detection channel were added in the optical
path. Fluorescence decays recorded at the series of k values
were fitted to a multi-exponential model function
Ik tð Þ ¼
XN
i¼1




where aiðkÞ is the i-th pre-exponential component and siðkÞ
is the relevant fluorescence lifetime. The fitting procedure
applied here assumed that the experimental decay curve is
the combination of the fluorescence decay function (1), the
background signal, and the contribution of the scattered exci-
tation light as described previously.32 The nonlinear least
squares approach using v2 and weighted residuals as the
goodness of fit criteria has shown that a 3-exponential model
(N¼ 3) is sufficient to provide an accurate representation of
the fluorescence decays. The recovered parameters ai kð Þ and
si kð Þ were then used to create TRES. The time resolved
emission spectra It kð Þ were obtained according to the follow-
ing equation:33,34
It kð Þ ¼
X3
i¼1







where S kð Þ is the steady-state spectrum of the sample. Each
S kð Þ spectrum has been corrected for a dark signal offset,
fluctuations in the lamp output, and the wavelength response
of the monochromator’s diffraction grating. In order to
obtain TRES as a function of wavenumber, the It kð Þ were
converted to It ð Þ by35,36
It ð Þ ¼ k2It kð Þ: (3)
In the next stage, the model of TRES gt ð Þ, based on the
Toptygin-type approach37 where the multiple normalised
Gaussian distributions were used to represent the spectral
shapes of fluorescent components









was fitted to the experimental spectra (3). Here, AiðtÞ is the
contribution of each component, iðtÞ is the peak position,
and riðtÞ is the half-width of the distribution. In practice, a
sum of 3 Gaussian distributions was fitted to the expression
3It ð Þ.
Fluorescence spectra of insulin at different times of
aggregation are shown in Fig. 1. The results cover the period
from about 20min after sample preparation up to over 600 h.
The intensity of the initial peak at about 300 nm gradually
decreases, and the spectrum becomes broader and shifts
towards longer wavelengths. Normalised spectra [Fig. 1(B)]
show at least three characteristic peak values about 300 nm,
315 nm, and 340 nm, indicating fluorescence from the prod-
ucts of the complex conformational changes, which cannot
be explained on the basis of the steady-state studies only.
The drop in Tyr fluorescence intensity is consistent with the
result reported by Bekard and Dunstan,13 except that in the
conditions of their experiment, pH 1.9 and temperature
60 C, the aggregation occurred within 10 h, while in our
experiment, pH 7.4 and 22 C, it takes about 30 days. This
result confirms that at physiological pH and in the presence
of Zinc ions, the insulin hexamer formation is stable, which
is exploited for stabilisation of insulin in neutral pH drug
product formulations.
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The fluorescence intensity decays of the insulin sample
were recorded at different wavelengths and at different points
of aggregation. Figure S1 in the supplementary material dem-
onstrates strong lifetime-wavelength dependence where the
fluorescence intensity decays measured at the short wave-
length side of the spectrum (290 nm) decay more rapidly than
the decays measured at the longer wavelength side (350 nm).
This is consistent with the lifetime-wavelength correlation
observed in proteins.38,39 The effect may be explained by the
fluorescence intensity decay measured at the short-wavelength
side of the spectrum being accelerated by the peak of the tran-
sient emission spectrum shifting away from the detection
wavelength due to dielectric relaxation, thus causing a further
decrease in intensity. For the same reason, the decay detected
at the long-wavelength side of the spectrum decreases at a
slower rate, as the peak of the shifting transient emission spec-
trum moves towards the detection wavelength. However, the
detailed analysis of the recovered fluorescence lifetimes si(k)
[see Table S1 and Fig. S1(C) in the supplementary material]
shows that although the non-significant increase in two shorter
lifetimes si(k) is typical for the lifetime-wavelength depen-
dence, the strong increase in the longest lifetime has to be a
consequence of significant structural change. The comparison
of Figs. S1(A) and S1(B) and the differences in the si(k) in
Fig. S1(C) show that the lifetime components of insulin after
690 h of aggregation have increased as compared to the
lifetimes observed at 0.35 hours (21min). This is likely to be
due to numerous effects related to the complexity of insulin
photophysics. Indeed, insulin has four tyrosine residues and
three of them are buried in the protein40 and therefore can be
simultaneously involved in both hydrophobic and hydrophilic
interactions. Therefore, the alterations in the local environ-
ments of the tyrosines at different stages of insulin aggrega-
tion are likely to result in more complex fluorescence kinetics.
Nevertheless, because the fluorescence lifetime components
si(k) are dependent on k, the decay associated spectra (DAS)
technique, assuming the spectrum to be the sum of the station-
ary spectra of few different forms, is not applicable and the
TRES approach is needed.
TRES It ð Þ were determined for the insulin sample at
different times after its preparation. The examples of the
3It ð Þ plots vs. time for the fresh (0.35 hours after prepara-
tion) sample and the old (690 h after preparation) sample are
shown in Figs. 2(A) and 2(B), respectively. Both sets of plots
3It ð Þ display peaks around 33 000 cm1 whose intensities
gradually decrease with time after excitation. The main dif-
ference between both samples is the emergence of a broader
structure at shorter wavenumbers observed in the old sample.
This is better demonstrated in the normalised plots of Figs.
2(C) and 2(D) where it appears at 30 000 cm1.
To obtain fuller and quantitative information on the
observed spectral changes, all 3It ð Þ spectra were modelled
FIG. 1. Fluorescence spectra of 50lM
insulin in PBS buffer at selected times
of 0, 261, 310, 357, 459, and 621 h
after sample preparation (A) and the
normalised spectra (B).
FIG. 2. TRES spectra of (A) 0.35 and
(B) 690 h old insulin samples deter-
mined at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3,
4, 5, 6, 7, 8, 9, and 10 ns after excita-
tion. Plots (C) and (D) show the same
spectra after normalisation.
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by the sum of 3 normalised Gaussian profiles (the sum of two
Gaussians fitted poorly to the experimental data, while the v2
values obtained for the triple-Gaussian fitting were in the
acceptable range of 1.00–1.19. Figure S2 (supplementary
material) shows the examples of fitting the triple-Gaussian
function to the data obtained for the fresh and old samples (as
in Fig. 2) for the times 0.25 ns and 10 ns after excitation. The
fresh sample shows initially (at 0.25 ns after excitation) two
emitting species with the maxima around 34 000 and
33 000 cm1 (as recovered from Gaussian fitting) and, after
10 ns, the additional component with the peak at 30 000 cm1.
In the old sample, the initial spectrum shows three peaks: at
34 000 and 33 000 cm1 as in the fresh sample and the domi-
nating component with the peak at 31 000 cm1. After 10 ns,
this peak shifts to around 29 500 cm1.
The above observations seem to be consistent with compi-
lation of two processes characteristic of proteins:21 excitation-
triggered conformational change of insulin molecules on a
nanosecond time scale and their aggregation in the time-scale
of several hours to days.
As can be seen in Fig. 2(D), there is no gradual shift of
the spectrum on the nanosecond scale, which would be con-
sistent with the dielectric relaxation, but the spectrum is
rather a sum of two profiles with the maxima at 33 000 cm1
and 30 000 cm1, which suggests that the 30 000 cm1 pro-
file is the conformational form. On the other hand, the origin
of the profile with the peak at 31 000 cm1 in the initial spec-
trum of the old sample [Fig. S2(C), supplementary material]
can be explained as the result of aggregation of the mole-
cules that emitted at 33 000 cm1 before their aggregation.
This also explains the reduced intensity of the 33 000 cm1
band. The aggregates also seem to undergo a conformational
change in a ns time scale, which causes further shift of their
spectra maximum to about 29 500 cm1 as is seen in the old
sample TRES at 10 ns [Fig. S2(D), supplementary material].
The peaks of the Gaussian profiles fitted to the experi-
mental 3It ð Þ curves are plotted in Fig. 3(A). The loca-
tions of peaks emitting around 34 000 cm1 and 33 000 cm1
seem to be weakly dependent on the age of the sample and
show a non-significant spectral shift towards longer wave-
lengths which is consistent with the effect of dielectric relax-
ation. Indeed, contrary to most of the fluorophores for which
dielectric relaxation is much faster than fluorescence decay,
the dielectric relaxation of intrinsic fluorophores like
tyrosine and tryptophan in proteins usually occurs on the
same nanosecond time scale as fluorescence which leads to
more complex photophysics.
The spectral shifts of the third component, however, are
unlikely to be due the dielectric relaxation because their val-
ues are significant, some emission about 33 000 cm1
remains in the spectrum at later times, and the shift of the
peak vs. time dependence does not always have a dielectric
relaxation exponential character but a sigmoidal shape in
some cases. Therefore, we currently interpret the spectral
shifts of the third component as a result of the excitation-
triggered conformational changes of the insulin aggregates.
The variations in the third peak position vs. time plots
observed at different ages of the sample may be explained by
different compositions of the insulin aggregates during its
aging.
Since our model of the insulin fluorescence spectra [Eq.
(4)] uses the normalised Gaussian distribution functions, the
amplitudes Ai(t) represent the contributions of fluorescence
from three components. Consequently, the time decays of
Ai(t) can be regarded as the fluorescence decay of these com-
ponents. Figure 3(B) shows the Ai(t) decays observed in the
oldest sample. Exponential fitting of these curves gives the
fluorescence lifetimes of the 34 000 cm1 and 33 000 cm1
forms as 0.96 ns and 1.10 ns, respectively, while the fluores-
cence lifetime of the conformational form is longer—
1.39 ns. Note that these values are substantially shorter than
the longest lifetime components recovered from the raw
decays [Fig. S1(C) and Table S1 in the supplementary mate-
rial], which shows how effects like dielectric relaxation and
conformational change in the fluorophore may complicate
interpretation of the lifetime data.
By using the TRES technique, we have provided a new
insight into the tyrosine fluorescence kinetics of bovine insu-
lin during its aggregation. We have observed the fluores-
cence of two forms showing peak emission at 34 000 cm1
and 33 000 cm1 and the fluorescence of the product of con-
formational change of the 33 000 cm1 form with the peak
emission at 30 000 cm1. As the insulin solution ages, the
aggregation of the 33 000 cm1 form occurs resulting in the
shift of the initial aggregate emission peak to 31 000 cm1.
The aggregates also undergo conformational change after
excitation leading to the emission with the peak shifted to
29 000 cm1. Identification and further characterisation of
FIG. 3. (A) Time evolution of the peak positions of the fluorophores emitting at 34 000 cm1 (dotted line), 33 000 cm1 (dashed line), and 30 000 cm1 (solid
line) after excitation for the sample measured after 0.35 (), 22 (), 68 (), 93 (), and 690 ($) h of aggregation. Plot (B) shows time evolution of the
contributions of Gaussian components Ai(t) in the oldest sample. Shown are the forms with the initial peak at 34 000 cm
21 (), 33 000 cm21 (), and
30 000 cm21 ().
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the fluorescent insulin forms will require further TRES stud-
ies for the samples at different concentrations, temperatures,
and pH conditions. Nevertheless, we have demonstrated that
tracking the changes in the intrinsic fluorescence offers a
sensitive way of studying unfolding and aggregation of insu-
lin when not modified by extrinsic markers and in the undis-
turbed clinically relevant environment, for example, inside a
plastic delivery cannula or within a storage vial.
See supplementary material for the fluorescence inten-
sity decays of the fresh and older insulin samples (detected
at different emission wavelengths) and the changes in the
recovered lifetimes (Fig. S1, supplementary material), exam-
ples of fitting the model of TRES [Eq. (4)] to the actual spec-
tra (Fig. S2, supplementary material), and the results of
fitting the fluorescence intensity decays Ik(t) of the insulin
sample recorded at different wavelengths and at different
points of aggregation (Table S1, supplementary material).
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